Rigel Pharmaceuticals, Inc. (RIGL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 109 | 149 | 120 | 117 | 179 | 294 | 277 | 306 |
| Operating profit | $m | 125 | 87 | ||||||
| Net profit | $m | -30 | -18 | -59 | -25 | 17 | 367 | 322 | - |
| EPS reported | $ | 20.40 | 16.32 | ||||||
| Operating cashflow per share | $ | 4.21 | 4.28 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 4.21 | 4.28 | ||||||
| Free cash flow | $m | 76 | 79 | ||||||
| Net debt | $m | -102 | -56 | ||||||
| Book value equity | $m | 391 | 425 | ||||||
| Book value per share | $ | 20.78 | 21.74 | ||||||
| Number of shares | m | 18.84 | 19.57 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 2.20 | 2.95 | ||||||
| P/B LTM | x | 1.97 | 1.81 | ||||||
| P/S LTM | x | 2.62 | 2.78 | ||||||
| P/FCF LTM | x | 10.18 | 9.70 | ||||||
| EV/EBITDA LTM | x | 5.95 | 8.33 | ||||||
| EV/Sales LTM | x | 2.66 | 2.77 | ||||||
| Earnings Yield LTM | % | +45.45% | +33.90% | ||||||
| FCF Yield | % | +9.82% | +10.31% | ||||||
| Quality | |||||||||
| ROE | % | +93.75% | +96.49% | ||||||
| ROIC | % | +28.21% | +18.70% | ||||||
| Operating margin | % | +42.63% | +31.45% | ||||||
| Gross margin | % | +93.33% | +91.39% | ||||||
| FCF/Sales | % | +25.71% | +28.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +1548.5% | ||||||
| Sales Growth YoY | % | +64.15% | +54.39% | ||||||
| Net Income Growth YoY | % | +1999.1% | +1741.1% | ||||||
| FCF Growth | % | +143.46% | +155.48% | ||||||
| Operating Profit Growth | % | +418.63% | +259.83% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.42 | 1.99 | ||||||
| Net Debt/EBITDA | x | 0.10 | -0.22 | ||||||
| EBIT/Net interest | x | 17.14 | 15.00 | ||||||
| Net debt/market cap | % | +6.87% | +4.98% | ||||||
| Net debt/Equity | x | -0.26 | -0.13 | ||||||
| Gross debt/equity | x | 0.14 | 0.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rigel Pharmaceuticals, Inc. (RIGL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free